Cas:21431-24-3 2-methyl-benzothiazole-5-sulfonic acid acetylamide manufacturer & supplier

Chemical Name:2-methyl-benzothiazole-5-sulfonic acid acetylamide

CAS.NO:21431-24-3

Synonyms:5-N-Acetyl-sulfonamido-2-methyl-benzothiazol;2-Methyl-5-acetylsulfamylbenzothiazol

Molecular Formula:C₁₀H₁₀N₂O₃S₂

Molecular Weight:270.32800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.447g/cm3

Index of Refraction:1.633

PSA:112.75000

Exact Mass:270.01300

LogP:2.90120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-N-Acetyl-sulfonamido-2-methyl-benzothiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Methyl-5-acetylsulfamylbenzothiazol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methyl-5-acetylsulfamylbenzothiazol Use and application,5-N-Acetyl-sulfonamido-2-methyl-benzothiazol technical grade,usp/ep/jp grade.

Related News: Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients. O-ethyl (8-methyl-8-azabicyclo[3.2.1]octan-3-yl)sulfanylmethanethioate manufacturers Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients. 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol suppliers Given ICER’s uncertainty regarding efgartigimod’s dosing and long-term benefits, the group said it’s moderately certain the drug can produce a “comparable, small or substantial net health benefit” in that same group of MG patients. 4-chloro-1-[2,2-dichloro-1-(4-chlorophenyl)ethenyl]-2-methylsulfonylbenzene vendor & factory The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. ,CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication.